Comparative Pharmacology
Head-to-head clinical analysis: BONTRIL versus FASTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONTRIL versus FASTIN.
BONTRIL vs FASTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bontril (phendimetrazine) is a sympathomimetic amine that acts as an appetite suppressant. Its mechanism involves stimulating the hypothalamus to release norepinephrine and dopamine, which reduces hunger cues. It is a prodrug that is metabolized to the active agent phenmetrazine, which inhibits reuptake and increases release of norepinephrine and dopamine in the central nervous system.
Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.
BONTRIL 50 mg orally once daily, with or without food.
30 mg orally once daily in the morning, administered as a single dose.
None Documented
None Documented
18-24 hours; prolonged in renal impairment (up to 40 hours) requiring dose adjustment.
Terminal elimination half-life is approximately 16-20 hours for the immediate-release formulation. With sustained-release forms, effective half-life may extend to 24-34 hours due to prolonged absorption. Clinical context: time to reach steady state is about 3-5 days.
Primarily renal (60-70% unchanged) with minor biliary/fecal (10-15% as metabolites).
Primarily renal (approximately 70-80% unchanged) and biliary/fecal (20-30% as metabolites). Urinary excretion is pH-dependent; acidic urine increases elimination.
Category C
Category C
Sympathomimetic Anorectic
Sympathomimetic Anorectic